A Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Performance of [18F]FSPG PET/CT for the Assessment of Acute Allograft Rejection After Heart or Liver Transplantation
Latest Information Update: 25 Jul 2023
Price :
$35 *
At a glance
- Drugs BAY 949392 (Primary)
- Indications Heart transplant rejection; Liver transplant rejection
- Focus Diagnostic use
- 18 Jul 2023 Status changed from recruiting to completed.
- 11 Dec 2020 Planned End Date changed from 31 Mar 2021 to 31 Mar 2023.
- 11 Dec 2020 Planned primary completion date changed from 31 Mar 2021 to 31 Mar 2023.